$Solventum(SOLV)$, the healthcare spin-off from $3M(MMM)$, recently released its first-quarter earnings report. While the headline numbers weren't disastrous, they did little to inspire confidence, leading me to seriously consider divesting my shares. Solventum reported flat to slightly positive sales growth, which is underwhelming considering their addressable market is estimated to be growing at 6% annually. This suggests they are failing to capture their fair share of the market. Despite this lackluster performance, Solventum boasts ambitious growth plans, including improving market share, evolving their sales model, and launching new products. However, the details surrounding these plans are scarce, m
Winning Trades
Share your positions with us! This is a column where you can find the winning trades of our fellow tigers. There probably are a few potential opportunities that you may have overlooked.
+ Follow
+122